FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, specifically to fusion proteins of CD95 domain, and can be used to inhibit CD95 signaling pathway. Fusion proteins containing N-terminally truncated forms of the CD95 extracellular domain was obtained, directly crosslinked to the Fc domain, wherein the functional fragment of N-terminally truncated extracellular domain of CD95 is located at N-terminus of Fc domain or functional fragment, and wherein fusion protein lacks additional N-terminal sequence.
EFFECT: with this invention it is possible to obtain fusion CD95 protein in stable form and efficiently inhibit CD95 signaling pathway.
13 cl, 8 dwg, 2 ex, 4 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITION COMPRISING MIXTURE OF CD95-FC ISOFROMS | 2013 |
|
RU2648157C2 |
| HETERODIMERIC IL-15 PROTEIN AND USE THEREOF | 2014 |
|
RU2689717C2 |
| INHIBITORS OF CD95 SIGNALING PATHWAY FOR TREATMENT OF MDS | 2013 |
|
RU2652348C2 |
| NUCLEOTIDE SEQUENCE CODING FUSED PROTEIN CONSISTING OF FUNCTIONAL FRAGMENT OF HUMAN IL-1RA AND CONSTANT PART OF HEAVY CHAIN OF HUMAN IgG4 | 2023 |
|
RU2821896C1 |
| SINGLE-STRANDED CD40 RECEPTOR AGONIST PROTEINS | 2016 |
|
RU2745801C2 |
| MONOCLONAL ANTI-CLAUDIN-18 ANTIBODIES FOR TREATING CANCER | 2008 |
|
RU2571923C2 |
| NUCLEOTIDE SEQUENCE CODING FUSED PROTEIN CONSISTING OF SOLUBLE EXTRACELLULAR FRAGMENT OF HUMAN PDGFRA AND CONSTANT PART OF HEAVY CHAIN OF HUMAN IGG4 | 2023 |
|
RU2821574C1 |
| ANTIGEN BINDING PROTEIN AND USE THEREOF AS ADDRESSING PRODUCT FOR TREATMENT OF CANCER | 2012 |
|
RU2659094C2 |
| ACTIVIN-ActRIIa-Fc ANTAGONISTS AND USE THEREOF FOR TREATING OR PREVENTING BREAST CANCER | 2008 |
|
RU2473362C2 |
| POLYPEPTIDES AND POLYNUCLEOTIDES AND THEIR USE FOR TREATMENT OF IMMUNE DISORDERS AND CANCER | 2012 |
|
RU2623161C2 |
